首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 2014年 8期 => 综述 =>索拉非尼联合肝移植、射频消融、肝..
索拉非尼联合肝移植、射频消融、肝动脉化疗栓塞治疗肝细胞癌的研究进展
Research advances in sorafenib combined with orthotopic liver transplantation, radiofrequency ablation, and transarterial chemoembolization in treatment of hepatocellular carcinoma
文章发布日期:2014年08月07日  来源:  作者:张明娟,刘佳,向晓星,等  点击次数:2022次  下载次数:385次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:肝细胞癌(HCC)是世界上最常见的恶性肿瘤之一,传统的手术及化疗效果局限。多酶抑制剂索拉非尼在HCC的Ⅲ期临床试验中证明对晚期肝癌有效,开创了肝癌治疗新领域。近年来,索拉非尼联合其他方法治疗HCC的研究正在世界各地开展,并取得令人鼓舞的结果。总结了索拉非尼联合肝移植、射频消融术及肝动脉化疗栓塞术治疗肝癌的研究进展,认为索拉非尼与其他抗肝癌治疗的综合运用,有望成为肝癌靶向治疗的新途径。
【Abstract】:Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide, and traditional surgery and chemotherapy provide limited benefit. Sorafenib, a multikinase inhibitor, was proved effective for advanced HCC in phase III clinical trial, which was a breakthrough in the treatment of HCC. In recent years, the studies on sorafenib combined with other therapies in the treatment of HCC have been conducted around the world, and inspiring results have been seen. The research advances in sorafenib combined with orthotopic liver transplantation, radiofrequency ablation, and transarterial chemoembolization in the treatment of HCC are summarized. It is thought that sorafenib combined with other anticancer therapies is expected to become a new approach of targeted therapy of HCC.
【关键字】:癌,肝细胞;索拉非尼;肝移植;导管消融术;化学栓塞,治疗性;综述
【Key words】:carcinoma, nepatocellular; sorafenib; liver transplantation; catheter ablation; chemoembolization, therapeutic; review
【引证本文】:

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号